-

Exscientia to Present at Upcoming Investor Conferences in March

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March:

  • Morgan Stanley EMEA HealthTech Conference. Management will participate in virtual investor meetings on Wednesday, March 1, 2023
  • Cowen 43rd Annual Healthcare Conference. Formal presentation on Tuesday, March 7, 2023, at 11:10 a.m. EST (4:10 p.m. GMT) in Boston, Massachusetts
  • Barclays Global Healthcare Conference. Fireside chat on Wednesday, March 15, 2023, at 3:05 p.m. EDT (7:05 p.m. GMT) in Miami, Florida

Live webcasts of the company presentations will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Contacts

Investor Relations Contact:
Sara Sherman
investors@exscientia.ai

Media Contact:
Oliver Stohlmann
media@exscientia.ai

Exscientia plc

NASDAQ:EXAI


Contacts

Investor Relations Contact:
Sara Sherman
investors@exscientia.ai

Media Contact:
Oliver Stohlmann
media@exscientia.ai

More News From Exscientia plc

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds have met the product profile requirements, set by both Exscientia and Sanofi, to enable a transition to the lead optimisation phase within the collaboration. Both programmes have also shown a high level of differentiation in earl...

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain. “As our precision-designed LSD1 and MALT1 inhibitors continue to progress towards the clinic, we are excited to share new preclinical data from both programmes,” said David Hallett, Ph.D., interim Chief Executive Officer and Chief Scientific Officer of Exscientia. “These posters, as well as an add...

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST). A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of...
Back to Newsroom